Category Regulatory

Taiho Pharma Licenses PI3Kα Inhibitor Risovalisib to Haihe Biopharma

Taiho Pharma and Haihe Biopharma Form Exclusive Japanese Partnership for PI3Kα Inhibitor Risovalisib Taiho Pharmaceutical Co., Ltd. (“Taiho”) and Haihe Biopharma Co., Ltd. (“Haihe”) today announced the signing of an exclusive license agreement for the development, manufacturing, and commercialization of…

Read MoreTaiho Pharma Licenses PI3Kα Inhibitor Risovalisib to Haihe Biopharma

Roche Showcases Breakthrough Data at ESMO 2025 Highlighting Scientific Advances and Transformative Progress in Cancer Care Across Multiple Tumor Types

Roche to Present Over 30 Oncology Abstracts at ESMO 2025, Showcasing Breakthroughs Across Major Cancer Types Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it will present more than 30 scientific abstracts spanning over 10 cancer types at the European…

Read MoreRoche Showcases Breakthrough Data at ESMO 2025 Highlighting Scientific Advances and Transformative Progress in Cancer Care Across Multiple Tumor Types
Prilenia

Prilenia and Ferrer to Present New Pridopidine Data in Huntington’s Disease at HSG Congress

Prilenia and Ferrer Highlight Compelling New Evidence of Pridopidine’s Disease-Modifying Potential in Huntington’s Disease at the 2025 HSG Congress Prilenia Therapeutics B.V. and Ferrer have jointly announced the presentation of five new scientific posters at the 2025 Huntington Study Group…

Read MorePrilenia and Ferrer to Present New Pridopidine Data in Huntington’s Disease at HSG Congress